Braftovi (Encorafenib) 75mg Capsules China | BRAF Inhibitor | GLT
Tap "Request a Quote" to open WhatsApp — the product details are already filled in. Just add your quantity and destination country.
- We reply within 24 hours with pricing, availability & COA
- Serves individuals and institutions worldwide
Prefer email? [email protected] · +86 15234153837
Generic Information: Braftovi (China-Mainland)
Braftovi (毕太维, encorafenib) is the China-Mainland originator brand of encorafenib, marketed in China by Laboratoires Pierre Fabre. It is supplied as 75 mg capsules in two pack sizes: 42 capsules and 168 capsules per box. Encorafenib is a selective BRAF kinase inhibitor targeting the BRAF V600E mutation, and in China it is approved for two indications — BRAF V600E-mutant metastatic colorectal cancer and BRAF V600E-mutant metastatic non-small cell lung cancer. As an imported originator oncology medicine, Braftovi requires a confirmed BRAF mutation test before use.
What Is Braftovi (Encorafenib) Used For?
In China-Mainland, Braftovi is approved for adults whose tumours carry a BRAF V600E mutation. It is used in combination with cetuximab for metastatic colorectal cancer after prior systemic therapy, and in combination with binimetinib for BRAF V600E-mutant metastatic non-small cell lung cancer. These are precisely the difficult-to-treat, later-line settings where a BRAF V600E mutation is found. Because the medicine targets only mutant BRAF, genomic confirmation of the mutation is the mandatory first step.
How Does Encorafenib Work?
Encorafenib selectively inhibits the mutant BRAF V600E kinase, turning off the abnormally switched-on MAPK signalling pathway that drives the growth of BRAF-mutant tumour cells. By interrupting this growth signal, the drug slows proliferation and promotes tumour-cell death while largely sparing normal cells. Pairing encorafenib with cetuximab or binimetinib hits the pathway at more than one point, improving depth and durability of response and delaying the emergence of resistance.
Indications
In China-Mainland, Braftovi has two approved indications. First, in combination with cetuximab, for adult patients with BRAF V600E-mutant metastatic colorectal cancer who have received prior systemic treatment. Second, in combination with binimetinib, for adult patients with BRAF V600E-mutant metastatic non-small cell lung cancer. These approvals rest on the NAUTICAL CRC and OCEAN II studies conducted in Chinese and Asian patients. Encorafenib is not indicated for BRAF wild-type tumours.
Dosage
The recommended adult dose of Braftovi depends on the indication: for non-small cell lung cancer it is 450 mg (six 75 mg capsules) once daily with binimetinib, and for colorectal cancer it is 300 mg (four 75 mg capsules) once daily with cetuximab. The 42-capsule box covers a one-week supply at the 300 mg dose and the 168-capsule box a four-week supply. Dosing adjustments depend on tolerability and laboratory results, and must follow the prescribing oncologist's instructions.
Side Effects
Common adverse reactions to encorafenib include fatigue, nausea, vomiting, diarrhoea, abdominal pain and reduced appetite. Skin reactions — rash, itching and the appearance of new skin lesions — are frequent and call for dermatological review. Patients may also experience fever, joint or muscle pain, headache and changes in liver enzymes or blood counts. Any new or changing skin growth, eye symptom or unusual bleeding should be reported to the treating doctor without delay.
Storage
Store Braftovi capsules at room temperature, protected from moisture and heat, in the original packaging. Keep out of the reach of children and check the expiry date before use. Refrigeration is not necessary.
Why Choose the China Version of Braftovi?
The China-Mainland Braftovi carries NMPA approval backed by dedicated Chinese and Asian clinical studies, giving patients and institutions a clearly documented, locally registered treatment pathway for BRAF V600E-mutant colorectal and lung cancer. Sourcing through GLT adds dependable verification of authenticity, current availability and complete export documentation, so cross-border procurement of this imported originator medicine stays straightforward, traceable and compliant.
How to Order
To source China-Mainland Braftovi (encorafenib) through GLT, contact us on WhatsApp at +86 15234153837 or email [email protected]. Tell us the pack size (42 or 168 capsules), the quantity and your destination country, and we will confirm current stock, sourcing origin and the import documentation required. A valid prescription and a confirmed BRAF V600E mutation report are required, and we serve both institutions and individual patients.
FAQ
Is Braftovi approved in China? Yes. Braftovi (encorafenib) is approved by China's NMPA for BRAF V600E-mutant metastatic colorectal cancer and non-small cell lung cancer, each in a specific combination.
Is encorafenib covered by medical insurance in China? As of the latest national drug list, encorafenib has not been included in China's national medical insurance reimbursement, so it is currently self-funded for most patients.
Which pack sizes are available? China-Mainland Braftovi is supplied as 75 mg capsules in 42-capsule and 168-capsule boxes.
Do I need a BRAF test before using encorafenib? Yes. A confirmed BRAF V600E mutation is required before treatment, as encorafenib does not work on BRAF wild-type tumours.
Is Braftovi a prescription medicine? Yes. Braftovi is a prescription oncology medicine and must be used under an oncologist's supervision.
What is the Chinese brand name of Braftovi? In China, Braftovi (encorafenib) is known as 毕太维 (Bitawei) and is marketed by Laboratoires Pierre Fabre.